OOIR: Observatory of International Research

Papers

(The H4-Index of Muscle & Nerve is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled	94
Small fiber neuropathy associated with SARS‐CoV‐2 infection	81
Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study	70
A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis	56
Parsonage Turner syndrome after COVID‐19 vaccination	56
Post COVID‐19 vaccine small fiber neuropathy	55
Multisystem proteinopathy: Where myopathy and motor neuron disease converge	39
Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy	39
Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy	36
Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes	35
Traumatic injury to peripheral nerves	33
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies	33
Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practice	33
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudy	32
COVID‐19 in patients with myasthenia gravis: Epidemiology and disease course	31
TS‐HDS and FGFR3 antibodies in small fiber neuropathy and Dysautonomia	31
(−)‐Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy	31
Tocilizumab is safe and tolerable and reduces C‐reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients	30
Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000‐2015	29
Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1	28
Nerve biopsy: Current indications and decision tools	28
Utilization of MG‐ADL in myasthenia gravis clinical research and care	28
Melatonin may slow disease progression in amyotrophic lateral sclerosis: Findings from the Pooled Resource Open‐Access ALS Clinic Trials database	27
Muscle fiber size in healthy children and adults in relation to sex and fiber types	27
Non‐length‐dependent small fiber neuropathy: Not a matter of stockings and gloves	26

Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders